| P50 | author | Katherine R. Calvo | Q55029498 |
| P2093 | author name string | Steven M Holland | |
| | Dennis D Hickstein | |
| | Thomas Hughes | |
| | Christa Zerbe | |
| | Fran Hakim | |
| | Juan Gea-Banacloche | |
| | Jennifer Grossman | |
| | Alexandra Freeman | |
| | Mark Parta | |
| | Kristen Cole | |
| | Jennifer Cuellar-Rodriguez | |
| P2860 | cites work | Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia | Q24634431 |
| | International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 |
| | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective | Q28388806 |
| | Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. | Q30368393 |
| | Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. | Q34192317 |
| | Reduced mortality after allogeneic hematopoietic-cell transplantation | Q34472861 |
| | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. | Q34505185 |
| | Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia | Q35249294 |
| | Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. | Q35266306 |
| | An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases | Q36727850 |
| | High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. | Q37023060 |
| | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 |
| | Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation | Q37552020 |
| | GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. | Q37564756 |
| | The evolution of cellular deficiency in GATA2 mutation | Q37564769 |
| | The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency | Q41821656 |
| | Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes | Q44175621 |
| | HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies | Q44468881 |
| | Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. | Q44666362 |
| | Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) | Q55671562 |
| | Emberger syndrome-Primary lymphedema with myelodysplasia: Report of seven new cases | Q57150841 |
| P433 | issue | 12 | |
| P921 | main subject | MonoMAC | Q6901244 |
| | stem cell transplantation | Q65592366 |
| P304 | page(s) | 1940-1948 | |
| P577 | publication date | 2014-08-09 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency | |
| P478 | volume | 20 | |